Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 1—January 2006
THEME ISSUE
Influenza
Prevention

Pandemic Influenza Threat and Preparedness1

Anthony S. Fauci*Comments to Author 
Author affiliation: *National Institutes of Health, Bethesda, Maryland, USA

Main Article

Figure 1

H5N1 cases in Asia, 2004–2005, among birds (dark gray) and humans (black) (1). A total of 137 laboratory-confirmed cases, including 70 deaths, occurred. This total includes 22 human cases and 14 deaths in Thailand, 93 human cases and 42 deaths in Vietnam, 4 human cases and 4 deaths in Cambodia, 13 human cases and 8 deaths in Indonesia, and 5 human cases and 2 deaths in China (1). A total of 137 laboratory-confirmed cases, including 70 deaths, occurred. This total includes 22 human cases and 14 d

Figure 1. H5N1 cases in Asia, 2004–2005, among birds (dark gray) and humans (black) (1). A total of 137 laboratory-confirmed cases, including 70 deaths, occurred. This total includes 22 human cases and 14 deaths in Thailand, 93 human cases and 42 deaths in Vietnam, 4 human cases and 4 deaths in Cambodia, 13 human cases and 8 deaths in Indonesia, and 5 human cases and 2 deaths in China (1). A total of 137 laboratory-confirmed cases, including 70 deaths, occurred. This total includes 22 human cases and 14 deaths in Thailand, 93 human cases and 42 deaths in Vietnam, 4 human cases and 4 deaths in Cambodia, 13 human cases and 8 deaths in Indonesia, and 5 human cases and 2 deaths in China.

Main Article

References
  1. World Health Organization. Confirmed human cases of avian influenza A(H5N1). 2005 [cited 2005 Oct 31]. Available from http://www.who.int/csr/disease/avian_influenza/country/en/
  2. World Health Organization. Avian influenza: assessing the pandemic threat. 2005 [cited 2005 Oct 31]. Available from http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/en/index.html
  3. Specter  M. Nature's bioterrorist. New Yorker. 2005;50–61.
  4. Webby  RJ, Webster  RG. Are we ready for pandemic influenza? Science. 2003;302:1519–22. DOIPubMedGoogle Scholar
  5. Monto  AS. The threat of and an avian influenza pandemic. N Engl J Med. 2005;352:323–5. DOIPubMedGoogle Scholar
  6. Stohr  K. Avian influenza and pandemics: research needs and opportunities. N Engl J Med. 2005;352:405–7. DOIPubMedGoogle Scholar
  7. Institute of Medicine. The threat of pandemic influenza: are we ready? 2004 Nov [cited 2005 Oct 21]. Available from http://www.iom.edu/report.asp?id=23639
  8. Couch  RB. An overview of serum antibody responses to influenza virus antigens. Dev Biol (Basel). 2003;115:25–30.PubMedGoogle Scholar
  9. Reid  AH, Taubenberger  JK, Fanning  TG. The 1918 Spanish influenza: integrating history and biology. Microbes Infect. 2003;3:81–7. DOIPubMedGoogle Scholar
  10. World Organization for Animal Health. Update on avian influenza in animals (type 5). 2005 Oct 28 [cited 2005 Oct 31]. Available from http://www.oie.int/downld/AVIAN%20INFLUENZA/A_AI-Asia.htm
  11. Food and Agriculture Organization. AIDE News: AI Bulletin. Update on the avian influenza situation (as of 1/9/2005). Issue no. 33. [cited 2005 Oct 31]. Available from http://www.fao.org/ag/againfo/subjects/documents/ai/AVIbull033.pdf
  12. Chen  H, Smith  GJ, Zhang  SY, Qin  K, Wang  J, Li  KS, Avian flu: H5N1 virus outbreak in migratory water fowl. Nature. 2005;436:191–2. DOIPubMedGoogle Scholar
  13. Liu  J, Xiao  H, Lei  F, Zhu  Q, Qin  K, Zhang  X, Highly pathogenic H5N1 influenza virus infection in migratory birds. Science. 2005;309:1206. DOIPubMedGoogle Scholar
  14. Kuiken  T, Rimmelzwaan  G, van Riel  D, van Amerongen  G, Baars  M, Fouchier  R, Avian influenza in cats. Science. 2004;306:241. DOIPubMedGoogle Scholar
  15. Keawcharoen  J, Oraveerakul  K, Kuiken  T, Fouchier  RA, Amonsin  A, Payungporn  S, Avian influenza in tigers and leopards. Emerg Infect Dis. 2004;10:2189–91.PubMedGoogle Scholar
  16. World Health Organization. Avian influenza: H5N1 detected in pigs in China. WHO Communicable Disease Surveillance and Response. 2004 Aug 20 [cited 2005 Oct 21]. Available from http://www.who.int/csr/don/2004_08_20/en/
  17. Olsen  SJ, Ungchusak  K, Sovann  L, Uyeki  TM, Dowell  SF, Cox  NJ, Family clustering of avian influenza A (H5N1). Emerg Infect Dis. 2005;11:1799–801.PubMedGoogle Scholar
  18. Ungchusak  K, Auewarakul  P, Dowell  SF, Kitphati  R, Auwanit  W, Puthhavathana  P, Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333–40. DOIPubMedGoogle Scholar
  19. World Health Organization. Avian influenza: situation updates. 2005 [cited 2005 Oct 21]. Available from http://www.who.int/csr/disease/avian_influenza/updates/en/
  20. Peiris  M, Yuen  KY, Leung  CW, Chan  KH, Ip  PL, Lai  RW, Human infection with influenza H9N2. Lancet. 1999;354:916–7. DOIPubMedGoogle Scholar
  21. Choi  YK, Ozaki  H, Webby  RJ, Webster  RG, Peiris  JS, Poon  L, Continuing evolution of H9N2 influenza viruses in southeastern China. J Virol. 2004;78:8609–14. DOIPubMedGoogle Scholar
  22. Centers for Disease Control and Prevention. Avian influenza infection in humans. 2005 Oct 17 [cited 2005 Oct 21]. Available from http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm
  23. Guo  Y, Li  J, Cheng  X. Discovery of men infected by avian influenza A H9N2 virus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1999;13:105–8.PubMedGoogle Scholar
  24. Fouchier  RA, Schneeburger  PM, Rozendaal  FW, Broekman  JM, Kemink  SA, Munster  V, Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101:1356–61. DOIPubMedGoogle Scholar
  25. Koopmans  M, Wilbrink  B, Conyn  M, Natrop  G, van der Nat  H, Vennema  H, Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004;363:587–93. DOIPubMedGoogle Scholar
  26. Food and Agriculture Organization. AIDE News: AI Bulletin. Update on the avian influenza situation (as of 12/05/2005). Issue no. 30. [cited 2005 Oct 21]. Available from http://www.fao.org/ag/againfo/subjects/documents/ai/AVIbull030.pdf
  27. Fauci  AS. Race against time. Nature. 2005;435:423–4. DOIPubMedGoogle Scholar
  28. National Institutes for Allergy and Infectious Diseases. Focus on the flu. 2005 Jun 21 [cited 2005 Oct 21]. Available from http://www2.niaid.nih.gov/Newsroom/FocusOn/Flu04/#resources
  29. Webby  RJ, Perez  DR, Coleman  JS, Guan  Y, Knight  JH, Govorkova  EA, Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet. 2004;363:1099–103. DOIPubMedGoogle Scholar
  30. Clements  ML, Betts  RF, Murphy  BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984;1:705–8. DOIPubMedGoogle Scholar
  31. La Montagne  JR, Fauci  AS. Intradermal influenza vaccination: can less be more? N Engl J Med. 2004;351:2330–2. DOIPubMedGoogle Scholar
  32. Belshe  RB, Newman  FK, Cannon  J, Duane  C, Treanor  J, van Hoecke  C, Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351:2286–94. DOIPubMedGoogle Scholar
  33. Kenney  RT, Frech  SA, Muenz  LR, Villar  CP, Glenn  GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295–301. DOIPubMedGoogle Scholar
  34. Ward  P, Small  I, Smith  J, Suter  P, Dutkowski  R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005;55(Suppl 1):i5–21. DOIPubMedGoogle Scholar
  35. National Center for Biotechnology Information. Influenza virus resource. 2005 Jun 23 [cited 2005 Oct 31]. Available from http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html
  36. Sloan  FA, Berman  S, Rosenbaum  S, Chalk  RA, Giffin  RB. The fragility of the U.S. vaccine supply. N Engl J Med. 2004;351:2443–7. DOIPubMedGoogle Scholar
  37. Poland  GA, Marcuse  EK. Vaccine availability in the US: problems and solutions. Nat Immunol. 2004;5:1195–8. DOIPubMedGoogle Scholar
  38. Muller  MP, McGeer  A, Straus  SE, Hawryluck  L, Gold  WL. Clinical trials and novel pathogens: lessons learned from SARS. Emerg Infect Dis. 2004;10:389–94.PubMedGoogle Scholar
  39. Finlay  BB, See  RH, Brunham  RC. Rapid response research to emerging infectious diseases. Nat Rev Microbiol. 2004;2:602–7. DOIPubMedGoogle Scholar
  40. National Institute of Allergy and Infectious Diseases. First US SARS vaccine trial opens at NIH. 2004 Dec 13 [cited 2005 Oct 21]. Available from http://www2.niaid.nih.gov/newsroom/releases/sarstrial.htm

Main Article

1This article is dedicated to the memory of John La Montagne, who died suddenly and unexpectedly in November 2004. Dr. La Montagne was the deputy director of NIAID and a world leader in the fields of influenza and emerging infectious diseases. He is sorely missed by his many colleagues.

Page created: February 16, 2012
Page updated: February 16, 2012
Page reviewed: February 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external